The significant rise in APLT's stock price is directly attributed to the positive outcomes of the Phase 3 INSPIRE trial for govorestat, which met its primary and key secondary endpoints. The successful trial results, coupled with the company's intention to seek FDA approval, have likely bolstered investor confidence, leading to a sharp increase in stock price. The data indicating govorestat's efficacy in reducing toxic sorbitol levels and improving patient mobility and well-being are critical factors driving the positive market reaction.